Vanguard Group Inc. Has $67.73 Million Stock Holdings in Disc Medicine, Inc. (NASDAQ:IRON)

Vanguard Group Inc. boosted its holdings in Disc Medicine, Inc. (NASDAQ:IRON - Free Report) by 1.8% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,068,246 shares of the company's stock after purchasing an additional 18,716 shares during the quarter. Vanguard Group Inc. owned approximately 3.59% of Disc Medicine worth $67,727,000 at the end of the most recent quarter.

Several other large investors have also recently added to or reduced their stakes in the stock. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its position in Disc Medicine by 21.6% during the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 18,649 shares of the company's stock worth $916,000 after acquiring an additional 3,312 shares during the period. State Street Corp increased its stake in Disc Medicine by 39.7% in the 3rd quarter. State Street Corp now owns 827,910 shares of the company's stock worth $40,683,000 after purchasing an additional 235,115 shares in the last quarter. Y Intercept Hong Kong Ltd acquired a new stake in shares of Disc Medicine during the third quarter valued at approximately $445,000. Barclays PLC lifted its holdings in shares of Disc Medicine by 123.7% in the third quarter. Barclays PLC now owns 40,145 shares of the company's stock valued at $1,972,000 after purchasing an additional 22,202 shares in the last quarter. Finally, Geode Capital Management LLC raised its position in Disc Medicine by 17.6% during the third quarter. Geode Capital Management LLC now owns 474,719 shares of the company's stock valued at $23,333,000 after buying an additional 70,983 shares during the period. 83.70% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In other news, insider Pamela Stephenson sold 3,137 shares of the stock in a transaction on Tuesday, February 18th. The stock was sold at an average price of $54.58, for a total transaction of $171,217.46. Following the sale, the insider now directly owns 69,529 shares of the company's stock, valued at approximately $3,794,892.82. This represents a 4.32 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Rahul Khara sold 7,500 shares of the company's stock in a transaction dated Monday, February 3rd. The stock was sold at an average price of $55.54, for a total transaction of $416,550.00. Following the sale, the insider now directly owns 14,035 shares of the company's stock, valued at $779,503.90. This represents a 34.83 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 361,690 shares of company stock valued at $19,648,094. 4.24% of the stock is owned by insiders.

Disc Medicine Stock Down 4.9 %

Shares of NASDAQ:IRON traded down $2.01 during midday trading on Wednesday, reaching $39.31. The company had a trading volume of 63,174 shares, compared to its average volume of 345,311. The stock has a market cap of $1.36 billion, a PE ratio of -9.88 and a beta of 0.77. Disc Medicine, Inc. has a 1-year low of $25.64 and a 1-year high of $68.73. The business's 50 day moving average price is $50.27 and its 200 day moving average price is $55.41.

Disc Medicine (NASDAQ:IRON - Get Free Report) last released its quarterly earnings data on Thursday, February 27th. The company reported ($0.98) EPS for the quarter, topping analysts' consensus estimates of ($1.06) by $0.08. On average, research analysts expect that Disc Medicine, Inc. will post -4.07 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have issued reports on IRON shares. Stifel Nicolaus increased their target price on shares of Disc Medicine from $90.00 to $94.00 and gave the stock a "buy" rating in a research report on Friday, January 24th. HC Wainwright reaffirmed a "buy" rating and set a $118.00 target price on shares of Disc Medicine in a research report on Tuesday, January 21st. Wedbush reaffirmed an "outperform" rating and issued a $90.00 price target (up from $83.00) on shares of Disc Medicine in a research report on Tuesday, January 21st. TD Cowen started coverage on shares of Disc Medicine in a research note on Thursday, February 27th. They issued a "buy" rating on the stock. Finally, Scotiabank boosted their price target on Disc Medicine from $73.00 to $75.00 and gave the company a "sector outperform" rating in a research note on Monday, March 3rd. Ten equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Buy" and a consensus target price of $93.80.

About Disc Medicine

Disc Medicine, Inc, together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis.